This is the first AI-based virtual patient for multiple myeloma, said Colin Hill, the Cambridge, Mass.-based company’s co-founder and chief executive. It is traditionally difficult to predict how specific drugs or combinations of drugs might help individual multiple myeloma patients, Mr. Hill said. That is why GNS Healthcare has spent over a decade building the Gemini platform, which could help match the right drug to the right patient, he said. Such an approach is called precision medicine. “It represents a tipping point where we’re starting to get the upper hand on unraveling the complexity of diseases and what’s going to work for who and when and why,” Mr. Hill said.